AMARIN CORP PLC\UK Stock-Based Compensation
AMARIN CORP PLC\UK (AMRN) reported Stock-Based Compensation of $4.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-29
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.10M, a 65.23% decline year-over-year.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.33M, a 46.13% decline year-over-year.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.61M, a 52.53% decline year-over-year.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.96M, a 58.37% decline year-over-year.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for fiscal 2025 was $13.94M, a 21.28% decline from fiscal 2024.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for fiscal 2024 was $17.70M, a 13.16% increase from fiscal 2023.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for fiscal 2023 was $15.65M, a 40.31% decline from fiscal 2022.
- AMARIN CORP PLC\UK share-based payment arrangement, noncash expense for fiscal 2022 was $26.21M, a 29.04% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $4.43M 10-Q · filed 2026-07-29 | $6.05M derived: sum of 3 quarters · filed 2026-07-29 | $8.00M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $2.33M 10-Q · filed 2026-04-29 | $3.95M derived: sum of 2 quarters · filed 2026-04-29 | $5.90M derived: sum of 3 quarters · filed 2026-04-29 | $11.94M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.57M derived: sum of 2 quarters · filed 2026-03-02 | $9.61M derived: sum of 3 quarters · filed 2026-07-29 | $13.94M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $8.00M derived: sum of 2 quarters · filed 2026-07-29 | $12.32M 10-Q · filed 2025-10-29 | $15.72M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $10.37M 10-Q · filed 2026-07-29 | $13.77M derived: sum of 3 quarters · filed 2026-07-29 | $18.47M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $4.33M 10-Q · filed 2026-04-29 | $7.73M derived: sum of 2 quarters · filed 2026-04-29 | $12.43M derived: sum of 3 quarters · filed 2026-04-29 | $16.81M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.10M derived: sum of 2 quarters · filed 2026-03-02 | $12.49M derived: sum of 3 quarters · filed 2026-03-02 | $17.70M 10-K · filed 2026-03-02 |
| 2024-09-30 | $4.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $9.09M derived: sum of 2 quarters · filed 2025-10-29 | $14.30M 10-Q · filed 2025-10-29 | $18.95M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $9.61M 10-Q · filed 2025-07-30 | $14.25M derived: sum of 3 quarters · filed 2026-03-02 | $17.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $5.22M 10-Q · filed 2025-05-07 | $9.87M derived: sum of 2 quarters · filed 2026-03-02 | $13.47M derived: sum of 3 quarters · filed 2026-03-02 | $15.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.26M derived: sum of 2 quarters · filed 2026-03-02 | $10.09M derived: sum of 3 quarters · filed 2026-03-02 | $15.65M 10-K · filed 2026-03-02 |
| 2023-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $5.44M derived: sum of 2 quarters · filed 2024-10-30 | $11.00M 10-Q · filed 2024-10-30 | $17.61M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $7.39M 10-Q · filed 2024-07-31 | $14.00M derived: sum of 3 quarters · filed 2025-03-12 | $18.88M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-03-31 | $5.56M 10-Q · filed 2024-05-01 | $12.17M derived: sum of 2 quarters · filed 2025-03-12 | $17.05M derived: sum of 3 quarters · filed 2025-03-12 | $25.69M derived: sum of 4 quarters · filed 2025-03-12 |
| 2022-12-31 | $6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $11.49M derived: sum of 2 quarters · filed 2025-03-12 | $20.14M derived: sum of 3 quarters · filed 2025-03-12 | $26.21M 10-K · filed 2025-03-12 |
| 2022-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $13.52M derived: sum of 2 quarters · filed 2023-11-01 | $19.60M 10-Q · filed 2023-11-01 | $29.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $8.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $14.72M 10-Q · filed 2023-08-02 | $24.83M derived: sum of 3 quarters · filed 2024-02-29 | $35.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $6.08M 10-Q · filed 2023-05-03 | $16.18M derived: sum of 2 quarters · filed 2024-02-29 | $26.61M derived: sum of 3 quarters · filed 2024-02-29 | $29.09M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $20.53M derived: sum of 2 quarters · filed 2024-02-29 | $23.01M derived: sum of 3 quarters · filed 2024-02-29 | $36.94M 10-K · filed 2024-02-29 |
| 2021-09-30 | $10.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $12.91M derived: sum of 2 quarters · filed 2022-10-27 | $26.84M 10-Q · filed 2022-10-27 | $38.34M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $16.40M 10-Q · filed 2022-08-03 | $27.91M derived: sum of 3 quarters · filed 2023-03-01 | $39.49M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $13.93M 10-Q · filed 2022-05-04 | $25.43M derived: sum of 2 quarters · filed 2023-03-01 | $37.02M derived: sum of 3 quarters · filed 2023-03-01 | $49.15M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $23.09M derived: sum of 2 quarters · filed 2023-03-01 | $35.22M derived: sum of 3 quarters · filed 2023-03-01 | $45.81M 10-K · filed 2023-03-01 |
| 2020-09-30 | $11.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $23.71M derived: sum of 2 quarters · filed 2021-11-03 | $34.30M 10-Q · filed 2021-11-03 | $42.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $12.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $22.72M 10-Q · filed 2021-08-05 | $30.91M derived: sum of 3 quarters · filed 2022-03-01 | $38.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $10.59M 10-Q · filed 2021-04-29 | $18.78M derived: sum of 2 quarters · filed 2022-03-01 | $26.74M derived: sum of 3 quarters · filed 2022-03-01 | $34.63M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $8.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $16.15M derived: sum of 2 quarters · filed 2022-03-01 | $24.03M derived: sum of 3 quarters · filed 2022-03-01 | $30.92M 10-K · filed 2022-03-01 |
| 2019-09-30 | $7.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $15.85M derived: sum of 2 quarters · filed 2020-11-05 | $22.73M 10-Q · filed 2020-11-05 | $27.50M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $7.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $14.77M 10-Q · filed 2020-08-04 | $19.54M derived: sum of 3 quarters · filed 2021-02-25 | $26.19M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $6.88M 10-Q · filed 2020-04-30 | $11.66M derived: sum of 2 quarters · filed 2021-02-25 | $18.31M derived: sum of 3 quarters · filed 2021-02-25 | $21.93M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $11.43M derived: sum of 2 quarters · filed 2021-02-25 | $15.04M derived: sum of 3 quarters · filed 2021-02-25 | $18.81M 10-K · filed 2021-02-25 |
| 2018-09-30 | $6.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $10.27M derived: sum of 2 quarters · filed 2019-11-05 | $14.03M 10-Q · filed 2019-11-05 | $17.52M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $3.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $7.38M 10-Q · filed 2019-07-31 | $10.87M derived: sum of 3 quarters · filed 2020-02-25 | $14.37M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $3.76M 10-Q · filed 2019-05-01 | $7.25M derived: sum of 2 quarters · filed 2020-02-25 | $10.75M derived: sum of 3 quarters · filed 2020-02-25 | $14.37M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $6.98M derived: sum of 2 quarters · filed 2020-02-25 | $10.61M derived: sum of 3 quarters · filed 2020-02-25 | $13.96M 10-K · filed 2020-02-25 |
| 2017-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $7.12M derived: sum of 2 quarters · filed 2018-11-01 | $10.47M 10-Q · filed 2018-11-01 | $13.71M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $6.98M 10-Q · filed 2018-08-01 | $10.21M derived: sum of 3 quarters · filed 2019-02-27 | $13.63M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $3.35M 10-Q · filed 2018-05-02 | $6.59M derived: sum of 2 quarters · filed 2019-02-27 | $10.00M derived: sum of 3 quarters · filed 2019-02-27 | $13.37M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $6.65M derived: sum of 2 quarters · filed 2019-02-27 | $10.02M derived: sum of 3 quarters · filed 2019-02-27 | $13.61M 10-K · filed 2019-02-27 |
| 2016-09-30 | $3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $6.78M derived: sum of 2 quarters · filed 2017-11-01 | $10.38M 10-Q · filed 2017-11-01 | $14.09M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $6.96M 10-Q · filed 2017-08-02 | $10.67M derived: sum of 3 quarters · filed 2018-02-27 | $14.59M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $3.60M 10-Q · filed 2017-05-03 | $7.31M derived: sum of 2 quarters · filed 2018-02-27 | $11.23M derived: sum of 3 quarters · filed 2018-02-27 | $14.44M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $7.63M derived: sum of 2 quarters · filed 2018-02-27 | $10.85M derived: sum of 3 quarters · filed 2018-02-27 | $13.89M 10-K · filed 2018-02-27 |
| 2015-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $7.13M derived: sum of 2 quarters · filed 2016-11-03 | $10.18M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $6.26M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $3.04M 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $9.02M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $14.69M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | $4.87M 10-Q · filed 2013-05-09 | $9.61M derived: sum of 2 quarters · filed 2013-05-09 | $14.24M derived: sum of 3 quarters · filed 2013-05-09 | $19.07M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $9.37M derived: sum of 2 quarters · filed 2013-02-28 | $14.20M derived: sum of 3 quarters · filed 2013-02-28 | $18.07M 10-K · filed 2013-02-28 |
| 2012-09-30 | $4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $9.47M derived: sum of 2 quarters · filed 2012-11-08 | $13.34M 10-Q · filed 2012-11-08 | $16.62M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-06-30 | $4.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $8.71M 10-Q · filed 2012-08-08 | $11.98M derived: sum of 3 quarters · filed 2013-05-09 | $14.64M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-03-31 | $3.87M 10-Q · filed 2013-05-09 | $7.15M derived: sum of 2 quarters · filed 2013-05-09 | $9.81M derived: sum of 3 quarters · filed 2013-05-09 | $11.63M derived: sum of 4 quarters · filed 2013-05-09 |
| 2011-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $5.93M derived: sum of 2 quarters · filed 2013-02-28 | $7.75M derived: sum of 3 quarters · filed 2013-02-28 | $9.29M 10-K · filed 2013-02-28 |
| 2011-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $4.48M derived: sum of 2 quarters · filed 2012-11-08 | $6.02M 10-Q · filed 2012-11-08 | $9.22M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $3.36M 10-Q · filed 2012-08-08 | $6.56M derived: sum of 3 quarters · filed 2013-02-28 | $7.32M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $1.54M 10-Q · filed 2012-05-08 | $4.74M derived: sum of 2 quarters · filed 2013-02-28 | $5.50M derived: sum of 3 quarters · filed 2013-02-28 | |
| 2010-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $3.96M derived: sum of 2 quarters · filed 2013-02-28 | $5.21M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $2.01M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $1.25M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $2.86M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |